Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped the treatment of obesity, with semaglutide and tirzepatide achieving mean body-weight reductions of 14.9% and 20.9% respectively in pivotal phase 3 trials. Yet a clinically important and under-examined consequence of their prin...
The Verdict
ClassificationLikely AI
ConfidenceMedium confidence
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/5710e0b5-5772-4bc8-ad2c-f29d3ae38b40)